| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $58,299,838 ) (Continued on the next page) |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy Ste 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | H7600185 | Ryan White Part C Outpatient EIS Program | 01 | 26 | HRSA | 7/8/2022 | $495,838 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | H7600185 | Ryan White Part C Outpatient EIS Program | 02 | 26 | HRSA | 7/12/2022 | $0 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy Ste 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | H7600185 | Ryan White Part C Outpatient EIS Program | 00 | 26 | HRSA | 12/7/2021 | $354,218 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy STE 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | K01OH011891 | Effects of residual PAH exposure from firefighters' turnout gear on plasma microRNA expression | 00 | 3 | CDC | 5/18/2022 | $108,000 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK128848 | Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment | 001 | 2 | NIH | 3/24/2022 | $46,257 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK128848 | Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment | 000 | 2 | NIH | 2/28/2022 | $416,265 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21ES031553 | Aeroallergens, Air Pollution and Respiratory Health in the Chickasaw Nation A1 | 000 | 2 | NIH | 4/12/2022 | $177,002 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01GM135547 | How Tetraspanins Regulate Sepsis | 001 | 3 | NIH | 6/29/2022 | $290,000 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01GM135547 | How Tetraspanins Regulate Sepsis | 000 | 3 | NIH | 6/27/2022 | $290,000 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy Ste 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | H1224834 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 00 | 10 | HRSA | 7/8/2022 | $534,587 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL152205 | A cardiac Wingless-Snail-Tep2 axis directs normal lipid homeostasis and protects against diet-induced obesity | 001 | 3 | NIH | 6/29/2022 | $36,250 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL152205 | A cardiac Wingless-Snail-Tep2 axis directs normal lipid homeostasis and protects against diet-induced obesity | 000 | 3 | NIH | 3/10/2022 | $326,250 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K01DK119375 | Investigating CD4 T regulatory cells during rapid cystogenesis | 000 | 3 | NIH | 4/26/2022 | $151,664 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21AI156351 | Deciphering DNA sequence selectivity in V(D)J recombination | 000 | 2 | NIH | 11/3/2021 | $180,125 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA253391 | Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | 001 | 2 | NIH | 5/3/2022 | $25,313 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA253391 | Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | 000 | 2 | NIH | 1/4/2022 | $284,764 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK121951 | Role of the Macrophage in Developmentally Programmed NAFLD | 000 | 3 | NIH | 5/25/2022 | $593,946 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA255840 | Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence | 001 | 2 | NIH | 4/28/2022 | $26,535 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA255840 | Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence | 000 | 2 | NIH | 12/10/2021 | $298,519 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA247234 | Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis | 000 | 3 | NIH | 5/9/2022 | $325,054 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA242168 | Biological impact of exclusive and dual e-cigarette use on oral cancer risk | 000 | 3 | NIH | 6/7/2022 | $482,730 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY030024 | Neuroprotection Mechanism for Photoreceptors | 000 | 4 | NIH | 7/5/2022 | $409,971 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY030513 | Essential Role of Very Long Chain Fatty Acids in Retinal Function | 000 | 4 | NIH | 7/1/2022 | $351,625 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P20GM134973 | Oklahoma Center for Microbial Pathogenesis and Immunity | 000 | 3 | NIH | 1/24/2022 | $1,950,020 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P20GM134973 | Oklahoma Center for Microbial Pathogenesis and Immunity | 002 | 3 | NIH | 8/4/2022 | $0 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P20GM134973 | Oklahoma Center for Microbial Pathogenesis and Immunity | 001 | 3 | NIH | 7/27/2022 | $216,668 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG068295 | Age-related vascular cognitive impairment: role of endothelial senescence | 000 | 3 | NIH | 7/26/2022 | $362,500 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R00AG056662 | IGF-1 Regulation of Astrocyte Mitochondrial Metabolism and Redox Homeostasis in Brain Aging | 001 | 4 | NIH | 6/14/2022 | $0 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R00AG056662 | IGF-1 Regulation of Astrocyte Mitochondrial Metabolism and Redox Homeostasis in Brain Aging | 000 | 4 | NIH | 5/20/2022 | $249,000 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA242845 | Blocking tumor progression in therapy-responsive RET aberration-associated cancer | 000 | 3 | NIH | 4/29/2022 | $382,759 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy Ste 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | 90DDUC0131 | Center for Learning and Leadership - University Center for Excellence in Developmental Disabilities | 00 | 1 | ACL | 7/8/2022 | $560,308 |
| | 2022 | 2022 | University Of Oklahoma | 865 Research Pkwy Ste 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | UH735353 | Regional Genetics Networks | 00 | 3 | HRSA | 3/28/2022 | $589,495 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG075834 | Effects of NAD restoration on neurovascular coupling in community dwelling older adults | 000 | 1 | NIH | 8/10/2022 | $653,661 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy STE 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | U1Q33082 | Geriatrics Workforce Enhancement Program | 00 | 4 | HRSA | 5/24/2022 | $749,221 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy STE 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | T3442150 | Primary Care Training and Enhancement-Community Prevention and Maternal Health | 00 | 2 | HRSA | 5/12/2022 | $431,433 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9933558 | Value-Based Medical Student Education Training Program | 01 | 4 | HRSA | 8/2/2022 | $0 |
| | 2022 | 2022 | University of Oklahoma | 865 Research Pkwy STE 530 | Oklahoma City | OK | 73104-3609 | OKLAHOMA | USA | T9933558 | Value-Based Medical Student Education Training Program | 00 | 4 | HRSA | 5/20/2022 | $1,175,832 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK130174 | Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment | 000 | 1 | NIH | 7/14/2022 | $395,452 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21AG072137 | A New Translational Rat Model for Evaluating Anti-Aging Interventions | 000 | 1 | NIH | 7/14/2022 | $185,188 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA273168 | Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold | 000 | 1 | NIH | 6/23/2022 | $612,099 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DA053342 | Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms | 000 | 1 | NIH | 5/6/2022 | $488,311 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY033866 | The unfolded protein response as a therapeutic target for fungal keratitis | 000 | 1 | NIH | 5/18/2022 | $364,953 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21CA274072 | Study Pro-Oncogenic Role of BCL6 in CLL Tumorigenesis | 000 | 1 | NIH | 7/7/2022 | $169,469 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K08CA266937 | Integrating pain-CBT into an mHealth analgesic support intervention for patients with chronic pain from advanced cancers | 000 | 1 | NIH | 6/29/2022 | $191,257 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01MH125998 | Regulation of Oxytocin Receptor Signaling in Neurons | 000 | 1 | NIH | 7/19/2022 | $42,500 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01MH125998 | Regulation of Oxytocin Receptor Signaling in Neurons | 000 | 1 | NIH | 7/19/2022 | $320,000 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA270234 | Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer | 000 | 1 | NIH | 7/25/2022 | $430,604 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21CA263838 | Leveraging mHealth to deliver integrated pain-CBT, opioid monitoring, and self-management support for advanced cancer patients coping with chronic pain | 000 | 1 | NIH | 4/13/2022 | $221,568 |
| | 2022 | 2022 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 530 | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK129656 | Understanding the metabolic pathology of pediatric obesity and NAFLD | 000 | 1 | NIH | 4/21/2022 | $596,036 |
|
